Thomas Nelius was born in Aschersleben, Germany, in 1967. He received an M.D. degree and a Ph.D. degree (magna cum laude) from the University Halle/Wittenberg (MLU), Halle/Saale, Germany in 1994 and 1995, respectively. He completed his residency in urology at a Teaching Hospital of the Otto-von-Guericke University Magdeburg, Germany and at the Princess of Wales Hospital, Bridgend, UK from 1994 till 2000. He is board certified by the German Board of Urology. From 2001 – 2003, T. Nelius was a Research Associate of the Department of Urology at Northwestern University Chicago, IL, USA, where he worked on the development of new antiangiogenic treatment strategies. Presently, he serves as an Assistant Professor at the Department of Urology at Texas Tech University Health Sciences Center, Lubbock, Tex, USA. His area of expertise includes also treatment of urological malignancies. He is mainly interested in new treatment strategies for prostate cancer, including, for example, metronomic chemotherapy with cyclophosphamide in patients with hormone-refractory prostate cancer, both preclinically and clinically; docetaxel-based chemotherapy in patients with prostate cancer; role of DICE-1 as tumor suppressor in prostate cancer; pigment epithelium derived factor in prostate cancer. He is an Active Reviewer for multiple medical journals and foundations including The Journal of Urology, The Scientific World Journal, Reviewer for the Israel Science Foundation, International Journal of Urology, International Medical Case Reports Journal, Drugs and Aging, Health Policy, Cancer Control: Journal of the Moffitt Cancer Center, Advances in Therapy, and Cancer Biomarkers.
Biography Updated on 17 January 2011